SciELO - Scientific Electronic Library Online

 
vol.28 número2Núcleo de Apoyo a la Salud de la Familia: promoción de la salud, actividad física y enfermedades crónicas en Brasil - encuesta nacional PMAQ 2013Tendencia de la incompletitud de las estadísticas vitales en el período neonatal, Estado de Rio de Janeiro, Brasil, 1999-2014 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Epidemiologia e Serviços de Saúde

versión impresa ISSN 1679-4974versión On-line ISSN 2337-9622

Resumen

CORREA, Flávia de Miranda et al. Target therapy versus dacarbazine in first-line treatment of advanced non-surgical and metastatic melanoma: budget impact analysis from the perspective of the Brazilian National Health System, 2018-2020. Epidemiol. Serv. Saúde [online]. 2019, vol.28, n.2, e2018325.  Epub 27-Jun-2019. ISSN 1679-4974.  http://dx.doi.org/10.5123/s1679-49742019000200013.

Objective:

to estimate the incremental budget impact of target therapy for first-line treatment of advanced non-surgical and metastatic melanoma compared to dacarbazine treatment.

Methods:

budget impact analysis, from the Brazilian National Health System (SUS) perspective; based on demographic data and incidence estimates, the population over a three-year time horizon (2018-2020) was delimited and the direct medical costs were estimated; the reference scenario was treatment with dacarbazine, and the alternative scenarios were target therapy with vemurafenib, dabrafenib, vemurafenib + cobimetinib and dabrafenib + trametinib; uncertainty assessment was conducted through scenario analysis.

Results:

the incremental budget impact ranged from R$ 451,867,881.00 to R$ 768,860,968.00, representing 0.70 to 1.53% of total SUS annual outpatient drugs expenditure; in best and worst scenario, results ranged from R$ 289,160,835.00 to R$ 1,107,081,926.00.

Conclusion:

the use of target therapy compared to dacarbazine implies an excessive impact on the budget, this bring unfovorable to its possible incorporation.

Palabras clave : Melanoma; Molecular Targeted Therapy; Dacarbazine; Costs and Cost Analysis; Brazilian National Health System.

        · resumen en Español | Portugués     · texto en Portugués | Inglés     · Inglés ( pdf ) | Portugués ( pdf )